candesartan has been researched along with Impaired Glucose Tolerance in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hypertensive patients with impaired glucose tolerance were randomly divided into two groups: group A (n = 6), which received 8 mg/day of oral candesartan for three months, and controls (n = 6)." | 9.13 | Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. ( Aizawa, Y; Nakagawa, O; Suzuki, K, 2008) |
| " Hypertensive patients with impaired glucose tolerance were randomly divided into two groups: group A (n = 6), which received 8 mg/day of oral candesartan for three months, and controls (n = 6)." | 5.13 | Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. ( Aizawa, Y; Nakagawa, O; Suzuki, K, 2008) |
| "Both TAK-536 and candesartan suppressed the increase in plasma glucose level in the OGTT without significant change in insulin concentration and improved insulin sensitivity." | 3.74 | TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. ( Chen, R; Horiuchi, M; Imura, Y; Iwai, M, 2007) |
| "Candesartan treatment markedly reduced the mean arterial pressure of controls and glucose-intolerant rats." | 1.32 | Renoprotective effects of chronic candesartan treatment in uninephrectomized rat. ( Mozaffari, MS; Patel, KB; Schaffer, SW, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzuki, K | 1 |
| Nakagawa, O | 1 |
| Aizawa, Y | 1 |
| Makita, S | 1 |
| Abiko, A | 1 |
| Naganuma, Y | 1 |
| Moriai, Y | 1 |
| Nakamura, M | 1 |
| Mozaffari, MS | 1 |
| Patel, KB | 1 |
| Schaffer, SW | 1 |
| Iwai, M | 1 |
| Chen, R | 1 |
| Imura, Y | 1 |
| Horiuchi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for candesartan and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Glucose Intolerance; Gl | 2008 |
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles | 2008 |
2 other studies available for candesartan and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Renoprotective effects of chronic candesartan treatment in uninephrectomized rat.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Electrolytes; Glucose Intolerance; Kidney; Male; Nephre | 2003 |
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2007 |